Abstract
AbstractColistin remains an important antibiotic for the therapeutic management of drug-resistant Klebsiella pneumoniae. Despite the numerous reports of colistin resistance in clinical strains, it remains unclear exactly when and how different mutational events arise resulting in reduced colistin susceptibility. Using a bioreactor model of infection, we modelled the emergence of colistin resistance in a susceptible isolate of K. pneumoniae. Genotypic, phenotypic and mathematical analyses of the antibiotic-challenged and un-challenged population indicates that after an initial decline, the population recovers within 24 h due to a small number of “founder cells” which have single point mutations mainly in the regulatory genes encoding crrB and pmrB that when mutated results in up to 100-fold reduction in colistin susceptibility. Our work underlines the rapid development of colistin resistance during treatment or exposure of susceptible K. pneumoniae infections having implications for the use of cationic antimicrobial peptides as a monotherapy.
Publisher
Springer Science and Business Media LLC
Reference57 articles.
1. Gogry, F. A., Siddiqui, M. T., Sultan, I. & Haq, Q. M. R. Current update on intrinsic and acquired colistin resistance mechanisms in bacteria. Front. Med. 8, 1–19 (2021).
2. Olaitan, A. O., Morand, S. & Rolain, J. M. Mechanisms of polymyxin resistance: acquired and intrinsic resistance in bacteria. Front. Microbiol. 5, 1–18 (2014).
3. Murray, C. J. et al. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet 399, 629–655 (2022).
4. Chen, J., Zeng, Y., Zhang, R. & Cai, J. In vivo emergence of colistin and tigecycline resistance in carbapenem-resistant hypervirulent Klebsiella pneumoniae during antibiotics treatment. Front. Microbiol. 12, 702956 (2021).
5. Zhang, Y. et al. Emergence of colistin resistance in carbapenem-resistant hypervirulent Klebsiella pneumoniae under the pressure of tigecycline. Front. Microbiol. 12, 1–10 (2021).